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1 P2Y 2 receptor (P2Y 2 R) activation in vivo enhances neointimal hyperplasia in response to vascular injury. 2 We recently reported that P2Y 2 R deficiency prevents fatty streak lesion formation in apolipoprotein E null (ApoE −/− ) mice. 3 During atherosclerosis, inflammation-induced endothelial barrier dysfunction promotes lipoprotein and leukocyte transendothelial flux in the vascular wall. 4 Extracellular nucleotides acting on P2Y 2 R regulate the expression of vascular cell adhesion molecule (VCAM)-1, 5 one of the earliest molecular events in the pathogenesis of atherosclerosis. 6 These data suggest a prominent role for endothelial P2Y 2 R in the formation of atherosclerotic lesions. However, given that this nucleotide receptor is ubiquitously expressed in vascular and blood-derived cells, [7] [8] [9] [10] the relative contribution of endothelial P2Y 2 R to the pathogenesis of atherosclerosis is unclear. We hypothesized that endothelial cell (EC) P2Y 2 R contributes to atherosclerosis by conferring an endothelial inflammatory phenotype and promoting monocyte infiltration. In the present study, we have generated EC-specific P2Y 2 R-deficient mice on an ApoE −/− background and characterized the functional contribution of endothelial P2Y 2 R to the development of atherosclerosis.
We determined that in ApoE −/− mice, loss of EC P2Y 2 R inhibited the progression of atherosclerosis and increased smooth muscle cell (SMC) and collagen content in atherosclerotic plaques, resulting in the formation of a subendothelial fibrous cap. Mechanistically, we showed that endothelial P2Y 2 R deficiency decreased the proteolytic activity of matrix metalloproteinase (MMP)-2 and inhibited nitric oxide (NO) production, leading to significant increase in SMC migration.
Our findings suggest that targeted inhibition of this nucleotide receptor may increase plaque stability.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Generation of Mice With EndothelialSpecific Deletion of P2Y 2 Receptor
A conditional floxed allele of the murine P2Y 2 R genomic locus was generated by flanking the coding region of the P2Y 2 R gene with loxP sites ( Figure 1A ). The P2Y 2 R fl/fl mice were bred to cadherin 5-Cre (Cre) transgenic mice to generate EC P2Y 2 R-KO (P2Y 2 R fl/fl Cre −/+ ) and control P2Y 2 R fl/fl mice. All mice are on a C57BL/6 background. Immunostaining of the mouse aorta with antibodies against P2Y 2 R detected the presence of P2Y 2 R in both EC and SMC in control mice ( Figure 1A ). As expected, P2Y 2 R was expressed in SMC but not in EC in the aorta of EC P2Y 2 R-KO mice ( Figure 1B ), whereas no P2Y 2 R-positive staining was detectable in the aorta of total body P2Y 2 R knockout mice ( Figure 1B) . Western blot analysis of lysates from primary EC cultures further confirmed endothelial-specific knockout of the P2Y 2 R ( Figure 1C ). In addition, endothelial deletion of P2Y 2 R did not result in P2Y 2 R deletion from peripheral blood mononuclear cells ( Figure 1C ). The EC P2Y 2 R-KO mice and controls were born at the expected Mendelian ratios and exhibited no obvious developmental defects. These data indicated that the P2Y 2 R is efficiently and specifically deleted in the endothelial compartment of EC P2Y 2 R-KO mice.
Endothelial P2Y 2 Receptor Mediates Nucleotide-Induced Vasodilation
Because extracellular nucleotides evoke endothelium-dependent relaxation in the mouse aorta, 11 we used the EC P2Y 2 R-KO mice to clarify the role of the P2Y 2 R in this process. Aortic ring constrictions in response to KCl or phenylephrine were similar between control and EC P2Y 2 R-KO mice (Figure 2A ). Acetylcholine-induced dilations of phenylephrine preconstricted aortic arch rings were also not significantly different between the 2 groups ( Figure 3A) . However, the vasodilatory responses evoked by ATPγS were significantly smaller in the EC P2Y 2 R-KO mice compared with controls (56.5±3.8%, n=8 in controls versus 19.2±10.0%, n=5 in EC P2Y 2 R-KO; Figure 2B ). UTPγS (uridine 5'-triphosphate)-induced dilations were also significantly impaired in the EC P2Y 2 R-KO aortic rings (80.4±8.4%, n=7 in controls versus 43.6±13.7%, n=5 in EC P2Y 2 R-KO; Figure 2B ). Aortic rings in control and EC P2Y 2 R-KO mice showed complete relaxation in response to the P2Y 6 receptor agonist UDP (56.5±7.7%, n=9 in controls versus 66.4±11.5%, n=6 in EC P2Y 2 R-KO; Figure 2C) . Surprisingly, the P2Y 1 R agonist ADP, even at the highest concentration of 10 μM, dilated neither control nor EC P2Y 2 R-KO aortic rings ( Figure 2C ). These data together with the normal vasodilatory responses to acetylcholine demonstrate that although the P2Y 2 deficiency mice have reduced endothelial NO synthase (eNOS) activity, this is not sufficient to result in systemic arterial hypertension.
Endothelial P2Y 2 Receptor Deletion Attenuates eNOS Activity In Vivo but Does Not Result in Hypertension
Decreased eNOS activity and NO production are critical contributors to endothelial dysfunction. 12 Interestingly, extracellular nucleotides have also been implicated in the activation of eNOS, leading to NO generation and vasodilation. 13 To explore the mechanisms underlying the reduction of endothelium-dependent relaxation in response to nucleotides, we, therefore, examined the effect of EC P2Y 2 R deletion on eNOS expression and activity. Western blot analysis demonstrated a significant (**P<0.01) decrease in eNOS protein levels in the EC P2Y 2 R-KO mouse aorta compared with control mice ( Figure 2D ). The decreased eNOS protein expression correlated with a decrease in plasma nitrate levels in EC P2Y 2 R-KO mice ( Figure 2E ; **P<0.01). A tamoxifen-inducible endothelium-specific P2Y 2 -deficient mouse (Tie2-CreER T2 P2Y 2 R fl/fl ) has been previously reported to develop systemic hypertension.
14 Blood pressure measurements were, thus, recorded in our EC P2Y 2 R-KO mice to determine whether they also develop hypertension. Radio-telemetry monitoring of blood pressure and heart rate showed no difference between EC P2Y 2 R-KO and control mice (Table 1) . Likewise, acute blood pressure measurements showed no difference between control and EC P2Y 2 R-KO mice (Table 2) . Furthermore, transthoracic echocardiography revealed no significant difference in right ventricle diameter or thickness in 5-month-old EC P2Y 2 R-KO mice relative to control mice ( Table 3 ), indicating that these mice did not develop pulmonary hypertension. Likewise, left ventricle thickness and diameter were similar in mice of both genotypes. Additional parameters of LV function (% fractional shortening, mitral and aortic velocities) are also similar between groups (data not shown). The blood pressure data coupled with the lack of hypertrophy in both ventricles indicate a lack of systemic hypertension in EC P2Y 2 R-KO mice.
Together, these data demonstrate that endothelial P2Y 2 R deficiency strongly reduces eNOS activity in vivo, resulting in reduced NO formation, which was not accompanied by arterial hypertension. ). The mice were maintained on a standard chow diet for 25 weeks and analyzed for lipoprotein and atherosclerotic lesion characteristics. The 2 groups of mice did not differ significantly in body weight, total plasma cholesterol, or fasting lipoprotein profile (Table 4) , n=6, respectively; **P<0.01; Figure 3A ). These results demonstrate that endothelial deletion of P2Y 2 R reduces atherosclerotic plaque burden.
Loss of Endothelial
P2Y 2 Receptor Deficiency Attenuates Inflammation and Endothelial Barrier Dysfunction
We next determined the effect of EC P2Y 2 R deficiency on the cellular composition of atherosclerotic lesions. Immunostaining with the antimacrophage antibody Mac-3 revealed that macrophage plaque content in the aortic root lesions of EC P2Y 2 R/ ApoE −/− mice was reduced by >66% as compared with control mice (***P<0.001; Figure 3B and 3C). To determine the mechanisms underlying the reduced macrophage plaque content in EC P2Y 2 R/ApoE −/− mice, we examined the effect of endothelial P2Y 2 R deletion on the transmigration of peripheral blood monocytes across endothelial monolayers. As shown in Figure 3D , monocyte chemoattractant protein-1 increased monocyte transmigration across endothelial monolayers from control P2Y 2 R fl/fl mice, whereas loss of endothelial P2Y 2 R ( EC P2Y 2 R-KO mice) significantly impaired monocyte migration. Consistent with reduced plaque macrophage content, the percentage of lesion area positive for VCAM-1 staining was significantly reduced in the aortic root lesions of EC P2Y 2 R ApoE −/− mice (***P<0.001; Figure 3B and 3C). These results suggest that absence of endothelial P2Y 2 R attenuates endothelial barrier dysfunction under pathological conditions. To examine the effect of endothelial P2Y 2 R deletion on vascular integrity in vivo, mice were injected with Evans blue dye, and vascular permeability within the aorta was assessed by measuring leakage of the dye. As shown in Figure 3E , there was no significant (***P<0.001) difference in the amount of dye recovered between control and EC P2Y 2 R-KO mice on a wild-type background. In contrast, on an ApoE −/− background, loss of endothelial P2Y 2 R significantly reduced the amount of dye deposited in the aorta when compared with the control/ ApoE −/− mice ( Figure 3E , (***P<0.001). These results indicate that absence of endothelial P2Y 2 R attenuates endothelial barrier dysfunction under pathological conditions.
Endothelial P2Y 2 Receptor Deficiency Promotes Fibrous Cap Formation
The decrease in macrophage content observed in EC P2Y 2 R ApoE −/− mice suggested that there may be an overall increase in SMC or collagen content of the lesions. Total SMC content in EC P2Y 2 R ApoE −/− lesions measured by the SMC marker α-smooth muscle actin represented 18% of the total lesion area and was 2.2-fold higher that that seen in control/ApoE −/− mice (***P<0.001; Figure 4B and 4C). Cap-like structures were observed in EC P2Y 2 R/ApoE −/− atherosclerotic lesions but not in control/ApoE −/− lesions ( Figure 4A ). The increase in collagen content observed in EC P2Y 2 R/ApoE −/− mouse plaques correlated with a dramatic increase in the cross-section area stained with Masson's Trichrome (53.4±3.6% as compared with 23.6±2.0% in controls; ***P<0.001; Figure 4A through 4C). Our results strongly suggest that deletion of endothelial P2Y 2 R shifts plaque phenotype from an inflammatory status to a more stable plaque characterized by an abundance of SMC and fibrous connective tissue. 
Endothelial Deletion of P2Y 2 R Decreases MMP-2 Activity in Atherosclerotic Lesions
MMPs are thought to enhance migration and proliferation of SMC during early stages of the atherosclerotic process, while in advanced plaques, inflammation-derived proteolytic activity may weaken the plaque. As atherosclerotic lesions in EC P2Y 2 R/ApoE −/− mice exhibited increased SMC and collagen content compared with the lesions in ApoE −/− mice, we examined whether endothelial P2Y 2 R deficiency alter MMP proteolytic activity in atherosclerotic lesions of 25-week-old mice. Gelatin zymography analysis of protein extracts from the aortic arch revealed a significant (*P<0.05) decrease in MMP-2 activity in EC P2Y 2 R/ApoE −/− mice compared with control/ApoE −/− mice ( Figure 5A ). This reduction in MMP-2 activity was paralleled by a decrease in MMP-2 mRNA expression as demonstrated by quantitative polymerase chain reaction (***P<0.001; Figure 5B ). Pro-MMP-9 expression in the lesions was similar between control/ApoE −/− and EC P2Y 2 R/ ApoE −/− mice. However, MMP-9 proteolytic activity was not detected in the lesions. Protein and mRNA levels of tissue inhibitor of metalloproteinase-2 were significantly (**P<0.01) higher in the aortic arch of EC P2Y 2 R/ApoE −/− mice, whereas tissue inhibitor of metalloproteinase-1 expression levels were similar between the 2 genotypes ( Figure 5B and 5C ). These data indicate that endothelial P2Y 2 R deficiency inhibits MMP-2 activity in the atherosclerotic lesions in ApoE −/− mice.
Endothelial Deletion of P2Y 2 R Increases SMC Migration Ex Vivo
To explore the mechanisms underlying the increased accumulation of SMC in EC P2Y 2 R ApoE −/− lesions, we examined the effect of endothelial P2Y 2 R deletion on migration of SMC out of aortic explants. NO derived from ECs has been shown to inhibit SMC migration and proliferation. 15, 16 We, therefore, examined whether SMC migration is altered in EC P2Y 2 R-KO mice that exhibit reduced eNOS levels. We first established that aortic explants from EC P2Y 2 R-KO mice released significantly less NO in the culture medium than explanted aortas from control mice ( Figure 6A ; **P<0.01, n=7). About 90% of aortic explants from EC P2Y 2 R-KO mice exhibit migrating SMC at day 10 compared with only 65% in control/ ApoE −/− mice (**P<0.01; Figure 6B ). At day 7, an average of 15±4.3 (P<0.05; n=7) migrated cells per explant (P<0.05; n=7) was observed in EC P2Y 2 R/ApoE −/− mice compared with 6±2.2 migrated cells per explant (n=15) in control mice. Immunofluorescence staining indicated that the migrated cells expressed the SMC marker desmin and were negative for the EC marker CD31 (not shown). Notably, addition of the NO synthase inhibitor L-NAME (N ω -Nitro-L-arginine methyl ester hydrochloride; 10 mmol/L) to the culture media equally enhanced SMC migration out of the explants from the control mice such that there was no difference in the migration of P2Y 2 R and control cells ( Figure 6C ). These data indicate that loss of endothelial P2Y 2 R enhances SMC migration through decreased NO release, thereby, contributing to SMC accumulation in EC P2Y 2 R-KO lesions.
Discussion
To examine the contribution of endothelial P2Y 2 R to the pathogenesis of atherosclerosis, we generated mice harboring an EC-specific P2Y 2 R deletion mice on an ApoE −/− background. We demonstrated that on the ApoE −/− background, EC-specific P2Y 2 R deficiency attenuates endothelial barrier dysfunction and decreases both inflammation and the burden of atherosclerosis. Most notably, EC-specific P2Y 2 R deficiency increases SMC and collagen plaque content, leading to the formation of subendothelial fibrous cap. Mechanistically, endothelial P2Y 2 R deficiency decreases VCAM-1 expression, resulting in decreased recruitment of macrophages into the atherosclerotic plaques. Conversely, endothelial P2Y 2 R deficiency also decreases eNOS activity, resulting in reduced NO production and increased SMC migration. Futhermore, we demonstrated that EC-specific P2Y 2 R deficiency reduced MMP-2 proteolytic activity in atherosclerotic lesions in ApoE −/− mice. Thus, our data suggest that therapies directed against EC P2Y 2 R might decrease plaque burden and increase plaque stability.
Extracellular nucleotides are maintained at low levels because of rapid hydrolysis by ectonucleotidases. 17 Under physiological conditions, ATP released from the endothelium may exert a potent regulation on vascular tone. 18 Aortic rings from P2Y 2 receptor knockout mice (P2Y 2 R −/− ) exhibit impaired vasorelaxation in response to nucleotides. 11 In these mice, it was reported that ATP-induced dilation is mediated by both P2Y 1 and P2Y 2 receptors, while UTP-dependent vasodilation is attributed mostly to the P2Y 6 R. Because these P2Y 2 R −/− mice lack the P2Y 2 R in both endothelial and SMCs, in the present study, we sought to clarify the role of endothelial P2Y 2 R in endothelium-dependent relaxation. Using mice with EC-specific deletion of P2Y 2 R, we demonstrated that the vasodilatory effects of ATP and UTP are mainly mediated by endothelial P2Y 2 R. In addition, we established that P2Y 1 R is not involved in ATP-induced relaxation because ADP even at high concentrations could not elicit relaxation of aortic rings in either control or EC P2Y 2 R-KO mice. Furthermore, our results showed that acetylcholine-induced dilation of phenylephrine preconstricted aortic rings were similar between control and EC P2Y 2 R-KO mice, indicating that loss of endothelial P2Y 2 R does not result in generalized endothelial dysfunction. Although nucleotide-mediated vasomotor responses may vary among different vascular beds, 19 our findings reveal that endothelial P2Y 2 R is the main receptor that mediates ATP-and UTP-dependent vasodilation in the aorta.
Impaired endothelium-dependent vasodilation is associated with the development of essential hypertension in humans and mice.
19,20 P2Y 2 R −/− mice were found to develop salt-resistant hypertension, 21 and P2Y 2 R activation decreases blood pressure in mice. 22 Furthermore, a tamoxifen-induced endothelium-specific P2Y 2 -deficient mouse (Tie2-CreER T2 P2Y 2 R fl/fl ) was reported to develop spontaneous hypertension.
14 Interestingly, our EC P2Y 2 R-KO did not develop hypertension as assessed by either acute or chronic measurements of blood pressure and the lack of hypertrophy in either ventricle. We demonstrated that endothelial deletion of P2Y 2 R using Cre transgenic mice did not result in P2Y 2 R deletion from peripheral blood mononuclear cells. As Tie2-Cre-mediated deletion of P2Y 2 R may also lead to excision from P2Y 2 R bone marrow-derived cells, together these data suggest that it may be the loss of P2Y 2 R from bone marrow-derived cells that accounts for the development of hypertension in P2Y 2 R −/− mice. Heterologous bone marrow transplants into global P2Y 2 R −/− mice will be required to resolve this issue. Although our data suggest that loss of endothelial P2Y 2 R does not result in systemic hypertension, functional impairment of the vascular endothelium is found in most forms of cardiovascular diseases, including atherosclerosis. 1 Endothelial dysfunction is associated with increased leukocyte transmigration and increased permeability of endothelium. 1, 23 Significant amounts of extracellular ATP may locally accumulate in the vasculature during traumatic and pathological events, 7 and P2Y 2 R activation has been shown to induce a transient increase in venular permeability to albumin, 24 suggesting that the P2Y 2 R may play a role in regulating vascular permeability. Accordingly, we found that EC-specific P2Y 2 R deletion attenuated endothelial barrier dysfunction that occurs in ApoE −/− mice as evidenced by decreased Evans blue dye accumulation observed in EC P2Y 2 R/ApoE −/− mice compared control/ApoE −/− mice. In addition, monocyte transmigration across endothelial monolayers isolated from EC P2Y 2 R-KO mice was significantly decreased compared with ECs isolated from control mice. These data strongly imply that the decreased monocyte content of atherosclerotic lesions in EC P2Y 2 R/ApoE −/− mice is likely to be due at least in part to impaired monocyte transmigration. We have also shown that loss of P2Y 2 R attenuates VCAM-1 expression in ECs, 3 suggesting that decreased binding of the monocytes likely also contributes to the decreased monocytes seen in atherosclerotic plaques of EC P2Y 2 R/ApoE −/− mice. Significantly less VCAM-1-positive areas were also observed in atherosclerotic lesions in EC P2Y 2 R/ApoE −/− mice. We recently reported that global P2Y 2 R deficiency prevents fatty streak lesion formation in ApoE −/− mice. 3 Altogether, these data indicate that a major effect of endothelial P2Y 2 R deletion may be to reduce vascular inflammation.
The formation of fibrous caps in atherosclerotic lesions of EC P2Y 2 R/ApoE −/− mice was a major finding of the present study. SMC accumulation could be the result of both increased MMP activity and migration of vascular SMC. However, gelatin zymography showed significantly lower activity of MMP-2 in the lesions of 25-week-old EC P2Y 2 R/ ApoE −/− mice, and no MMP-9 activity was detected at this time point. The decrease in MMP-2 activity was paralleled by a significant increase in tissue inhibitor of metalloproteinase-2 protein and mRNA levels in the plaques. Although these data do not rule out a possible transient increase in MMP activity at an earlier stage of plaque development, they suggest that in mature plaques, decreased MMP2 activity in EC P2Y 2 R/ ApoE −/− mice could have a beneficial effect by increasing plaque stability. Despite the decreased MMP activity, we observed a significant increase in SMC migration of aortic segments from EC P2Y 2 R/ApoE −/− mice ( Figure 6B ), suggesting that the increased SMC content of the fibrous plaque may be because of increased SMC migration. We postulate that this occurs as a consequence of decreased endothelial NO. In support of this, studies have shown that transfection of eNOS gene into SMC can effectively inhibit their migration in response to chemotactic agents. 25 Futhermore, the difference in SMC migration between explants derived from the control and EC P2Y 2 R/ApoE −/− mice was abrogated in the presence of a specific eNOS inhibitor (L-NAME; Figure 6C ). Together, these findings suggest that EC-specific deletion of P2Y 2 R may be contributing to plaque stability by not only increasing its SMC content but also downregulating MMP-2 activity. . Endothelial deletion of P2Y 2 R decreases nitric oxide (NO) production but increases smooth muscle cell (SMC) migration from aortic explants. A, NO release from the aortic explants from control and EC P2Y 2 R-KO mice (n=7 for each genotype) was measured by determining the production of nitrite in the cultured medium after 4 days. Data represent mean±SEM, **P<0.01. B, Cell migration was expressed as percent of explants exhibiting at least 1 SMC outside the explant. SMC migration was significantly increased in explants from EC P2Y 2 R/ApoE −/− mice as compared with control/ApoE −/− mice (n=10 mice per group). *P<0.05, **P<0 .01,***P<0.001 by 2-tailed Student t test. C, SMC migration out of aortic explants in presence of the endothelial nitric oxide synthase (eNOS) inhibitor L-NAME (10 mmol/L) was similar in control and EC P2Y 2 R-KO mice. ApoE indicates apolipoprotein E; and P2Y 2 R, P2Y 2 receptor. mice compared with control/ApoE −/− (n=5, **P<0.01), whereas TIMP-1 protein levels were unchanged. ApoE indicates apolipoprotein E; and P2Y 2 R, P2Y 2 receptor.
In conclusion, this study shows that decreased VCAM-1 expression leading to impaired macrophage infiltration acting together with MMP-2 activity and increased SMC migration resulting from diminished eNOS activity could explain the beneficial effects on plaque stabilization observed in EC P2Y 2 R ApoE −/− mice. Thus, targeted inhibition of P2Y 2 R-mediated signals in ECs may be a viable approach to decrease plaque burden and improve plaque stability.
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